Literature DB >> 28267602

Management of Urinary Incontinence Following Suburethral Sling Removal.

Nirmish Singla1, Himanshu Aggarwal1, Jeannine Foster1, Feras Alhalabi1, Gary E Lemack1, Philippe E Zimmern2.   

Abstract

PURPOSE: We evaluated urinary incontinence outcomes following synthetic suburethral sling removal in women.
MATERIALS AND METHODS: We reviewed a prospectively maintained database of 360 consecutive women who underwent transvaginal suburethral sling removal from 2005 to 2015. We excluded patients with neurogenic bladder, nonsynthetic or multiple slings, prior mesh for prolapse, concomitant surgery during sling excision, urethral erosion or fistula, postoperative retention or less than 6-month followup. Demographics, sling type, indications for removal, time to removal and patient reported outcomes were recorded. Outcomes were stratified by incontinence type, including stress predominant, urge predominant and mixed urinary incontinence. Subsequent management was evaluated, including observation, minimally invasive outpatient interventions (bulking agents, neuromodulation or onabotulinumtoxinA) or more invasive surgery (autologous fascial sling or bladder suspension). No patients elected to receive a subsequent synthetic sling. Success was defined by responses to UDI-6 (Urogenital Distress Inventory) questions 2 and 3, self-reported satisfaction with continence at the last visit and no further intervention.
RESULTS: Of the 99 patients who met inclusion criteria 27 denied any subjective leakage after suburethral sling removal alone while 72 experienced some degree of incontinence after removal. Stress predominant urinary incontinence occurred in 26 patients, which was persistent in 7 and de novo in 19, urge predominant incontinence was noted in 14, which was persistent in 6 and de novo in 8, and mixed urinary incontinence occurred in 32, which was persistent in 13 and de novo in 19. Mean followup was 23 months (range 6 to 114). The success rate following a single minimally invasive intervention after suburethral sling removal was 81%, 86% and 75% in patients with stress predominant, urge predominant and mixed urinary incontinence, respectively.
CONCLUSIONS: Patients who undergo suburethral sling removal may show urinary control, or de novo or persistent incontinence with a higher predilection for stress predominant or mixed urinary incontinence. However, after a single minimally invasive intervention following suburethral sling removal the success rate reached 75% to 86%.
Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  device removal; suburethral slings; surveys and questionnaires; urethra; urinary incontinence

Mesh:

Year:  2017        PMID: 28267602     DOI: 10.1016/j.juro.2017.02.3341

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Functional outcomes of synthetic tape and mesh revision surgeries: a monocentric experience.

Authors:  Salima Ismail; Emmanuel Chartier-Kastler; Christine Reus; Jérémy Cohen; Thomas Seisen; Véronique Phé
Journal:  Int Urogynecol J       Date:  2018-08-01       Impact factor: 2.894

Review 2.  Outcomes collected in female pelvic floor surgical procedure registries and databases: a scoping review.

Authors:  Rasa Ruseckaite; Justin O Daly; Joanne Dean; Susannah Ahern
Journal:  Int Urogynecol J       Date:  2021-05-26       Impact factor: 2.894

3.  Road to recovery after transvaginal surgery for urethral mesh perforation: evaluation of outcomes and subsequent procedures.

Authors:  Casey G Kowalik; Joshua A Cohn; Andrea Kakos; Patrick Lang; W Stuart Reynolds; Melissa R Kaufman; Mickey M Karram; Roger R Dmochowski
Journal:  Int Urogynecol J       Date:  2018-01-29       Impact factor: 2.894

4.  Safety and efficacy of polydimethylsiloxane (Macroplastique®) in women with stress urinary incontinence: analysis of data from patients who completed three years follow-up.

Authors:  Gamal Ghoniem; Bilal Farhan; Mashrin Lira Chowdhury; Yanjun Chen
Journal:  Int Urogynecol J       Date:  2021-06-08       Impact factor: 2.894

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.